AIDS Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of AIDS Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
HIV/AIDS
Studies conducted at University of Liverpool on HIV/AIDS recently published
June 15th, 2009
"Treatment with ritonavir-boosted protease inhibitors or efavirenz and nucleoside analogues leads to rises in lipids, which might contribute to cardiovascular risk. A MEDLINE search for clinical trials of first-line HAART with standardized 48-week lipids data available for combinations of two nucleoside analogues identified 13 with additional boosted protease inhibitor (PI/r) regimens (n=5,281) and two with efavirenz (n=1,087)," scientists in Liverpool, the United Kingdom report. "Inverse-variance weighting was used to provide estimates of combined 48-week elevations in each lipid parameter. The trials were well balanced for mean baseline total cholesterol (155 mg/dL),...
Source: AIDS Weekly (2009-06-15)
|
